Integrated Functional Genomics: On the road to leishmaniasis control Dormy House

这项建议的目的是召开一个关于利什曼病的国际研讨会。 [利什曼病控制之路上的集成基因组学]2007年9月定义 未来开发疫苗和药物的后基因组研究战略 利什曼病。利什曼病是一种寄生虫病，在88个资源贫乏的国家流行， 据估计，全球有1200万人感染。利什曼病仅次于 疟疾在寄生原生动物中对社会经济发展的影响 戴利的负担是240万。与艾滋病传播的日益重叠导致艾滋病毒/艾滋病 利什曼原虫合并感染是一个日益严重的威胁，特别是在欧洲、印度和东非。 利什曼原虫基因组计划最近完成，我们研究免疫的能力取得了进展 实验模型和人体中的机制，并更好地理解 寄主-寄生虫相互作用的分子细胞生物学。与会者将包括领先的 实验和临床免疫学、疫苗学、寄生虫分子方面的国际人物 除了来自主要机构的代表外，还有细胞生物学、生物化学和药物设计 (TDR，DNDI(被忽视疾病药物研究所(世卫组织))，One World Health)；参与者将 包括来自疾病流行国家的科学家(23%)和年轻的研究人员(15%)。 总体而言，本次会议的目标是： 1.将参与利什曼病研究的主要科学家聚集在一起，在有利于 探索和发展未来十年的研究重点 2.综述利什曼原虫分子细胞生物学、生物化学、寄主病原体的研究现状 相互作用、宿主遗传学和免疫反应 3.制定基础研究的主要中短期目标(试验和 临床)，有很高的潜力转化为控制利什曼病的新途径。

The purpose of this proposal is to convene an international symposium on leishmaniasis [Integrated Genomics on the Road to Leishmaniasis Control] in September, 2007 to define future post-genomic research strategies for the development of vaccines and drugs against leishmaniasis. Leishmaniasis, a parasitic disease, is endemic in 88 resource-poor countries, with an estimated 12 million people infected world-wide. Leishmaniasis is second only to malaria amongst the parasitic protozoa in its impact on socio-economic development, with a DALY burden of 2.4 million. Increasing overlap with the spread of AIDS has resulting in HIV / Leishmania co-infections as an increasing threat, particularly in Europe, India and East Africa. The recent completion of Leishmania genome projects, advances in our ability to study immune mechanisms in experimental models and in humans, and a greater understanding of the molecular cell biology of the host-parasite interaction. Attendees will include leading international figures in experimental and clinical immunology, vaccinology, parasite molecular cell biology, biochemistry and drug design in addition to representatives from major agencies (TDR, DNDi (Drugs for Neglected Disease Institute (WHO)), One World Health); participants will include scientists from disease endemic countries (23%) and young investigators (15%). Overall, the objectives for this meeting are: 1. To bring together key scientists involved in leishmaniasis research, in a setting conducive to exploring and developing research priorities over the coming decade 2. To review the state of the art in Leishmania molecular cell biology, biochemistry, hostpathogen interactions, host genetics and immune response 3. To formulate key short and medium term objectives for basic research (experimental and clinical), with high potential for translation into new avenues for leishmaniasis control.